Fulgent Genetics, Inc. FLGT
Set alert
19.53 USD +0.23 +1.22%
As of Nov 3, 10:17 AM ET
19.19 Day range 19.70
13.46 52-week range 31.04
- YTD
- -25.68%
- 1 year
- -15.51%
- Open
- 19.41
- Prev close
- 19.29
- Mkt cap
- 537.10M
- Vol
- 16.31K
- Avg vol
- 285.83K
- EPS
- -2.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.19
- High
- 19.70
- Forward P/E
- -36.45
- Beta
- 1.51
- Short ratio
- 2.87
- Inst. own
- 54.30%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 19.48
- 200-d avg
- 21.08
- 1y target
- 27.67
Analyst view
Consensus: none
Price target (mean) 27.67 +41.7% upside
Now 19.53
- Target (low)
- 26.00
- Target (mean)
- 27.67
- Target (high)
- 30.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.369 | -0.61 – -0.12801 | 0.28 | -231.8% | 75.39M | +6.9% | 2 |
| Next quarter | -0.12758 | -0.21 – -0.05274 | -0.01 | -1175.8% | 73.89M | +14.6% | 3 |
| Current year | -0.16188 | -0.65 – 0.32624 | -0.41 | +60.5% | 282.23M | -2.4% | 2 |
| Next year | -0.46394 | -0.66 – -0.28183 | -0.16188 | -186.6% | 324.21M | +14.9% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Mar 6, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Dec 7, 2023 | UBS | Initiated | — | Neutral |
| Oct 16, 2023 | Piper Sandler | Maintained | Neutral | Neutral |
| Mar 2, 2023 | Credit Suisse | Maintained | — | Outperform |
| Dec 8, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Nov 18, 2022 | Raymond James | Initiated | — | Outperform |
| Nov 14, 2022 | Credit Suisse | Maintained | — | Outperform |
| Nov 14, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 25, 2022 | Credit Suisse | Initiated | — | Outperform |
| May 16, 2022 | Piper Sandler | Maintained | — | Overweight |
| Jan 25, 2022 | Oppenheimer | Maintained | — | Outperform |
| Aug 10, 2021 | Credit Suisse | Maintained | — | Underperform |
| Mar 5, 2021 | Piper Sandler | Maintained | — | Overweight |
| Feb 1, 2021 | Oppenheimer | Maintained | — | Outperform |
| Jan 8, 2021 | Credit Suisse | Downgrade | Neutral | Underperform |
| Nov 24, 2020 | BTIG | Downgrade | Buy | Neutral |
| Sep 25, 2020 | Credit Suisse | Maintained | — | Neutral |
| Aug 20, 2020 | Oppenheimer | Initiated | — | Outperform |
| Jul 27, 2020 | Piper Sandler | Maintained | — | Overweight |
| Jun 17, 2020 | Piper Sandler | Maintained | — | Overweight |
| May 29, 2020 | BTIG | Initiated | — | Buy |
| May 5, 2020 | Credit Suisse | Maintained | — | Neutral |
| Nov 5, 2019 | Piper Sandler | Upgrade | Neutral | Overweight |
| Apr 26, 2019 | Credit Suisse | Downgrade | Outperform | Neutral |
| May 9, 2018 | Credit Suisse | Maintained | Outperform | Outperform |
| Mar 1, 2018 | Piper Sandler | Downgrade | Overweight | Neutral |
| Mar 1, 2018 | Credit Suisse | Maintained | Outperform | Outperform |
| Nov 7, 2017 | Credit Suisse | Maintained | — | Outperform |
| Aug 8, 2017 | Credit Suisse | Maintained | — | Outperform |